Andreas Emmenegger has been CFO of Molecular Partners since 2007. Prior to that, he was CFO of Glycart Biotechnology AG, where he had a leading role in the company’s CHF 235 million trade sale to F. Hoffmann-La Roche AG in 2005. Andreas went on to oversee strategic financial alliances for Roche Headquarters in Switzerland. He has more than 20 years of experience as a CFO of several public and private multinational companies, 15 of which were specifically in the biotech industry. In these CFO roles, he raised CHF 1 billion overall through public and private primary offerings and secondary transactions. He led the IPOs on the SIX Swiss Exchange of Molecular Partners in 2014 and of Interroll Holding AG in 1997. In addition, Andreas has more than 10 years of international industry experience in banking, capital markets, mergers and acquisitions, and human resources. Since 2016, he has been a member of the board of directors of Luzerner Kantonalbank, Switzerland, a publicly listed bank. Andreas holds a degree in finance, economics and business administration as well as an Executive MBA degree from IESE Business School, Barcelona.